Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 3

Кардиоцентрический и глюкозоцентрический принципы терапии сахарного диабета 2-го типа как единство и борьба противоположностей
К.В. Овсянников

References

1. Consoli A, Czupryniak L, Duarte R, Jermendy G, Kautzky‐Willer A, Mathieu C, Melo M, Mosenzon O, Nobels F, Papanas N, Roman G, Schnell O, Sotiropoulos A, Stehouwer CDA, Tack CJ, Woo V, Fadini GP, Raz I. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: expert opinion from a European consensus panel. Diabetes, Obesity and Metabolism 01 June 2020. Available from: https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14102 Accessed 2021 Feb 17.
2. Demidov NA. Patient on insulin therapy: what is he like? The data of the register. The 10th Interregional Conference "Algorithms for diagnosis and treatment of endocrine diseases". Moscow, 2020 Dec 12-13.
3. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus 2018;21(3):144-59 (In Russian).
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 2008 Oct;359(15):1577-89.
5. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011 Jul;343:d4169.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug;321(7258):405-12.
7. Dailey G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clinical Therapeutics 2011 Jun;33(6):665-78.
8. Bakke Å, Dalen I, Thue G, Cooper J, Skeie S, Berg TJ, Jenum AK, Claudi T, Fjeld Løvaas KF, Sandberg S. Variation in the achievement of HbA1c, blood pressure and LDL cholesterol targets in type 2 diabetes in general practice and characteristics associated with risk factor control. Diabetic Medicine 2020 Sep;37(9):1471-81.
9. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 2011 May;34 (Suppl 2):S101-6.
10. NIH; U.S. National Library of Medicine. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/home Accessed 2021 Feb 17.
11. Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. The Lancet. Diabetes & Endocrinology 2017 Sep;5(9):709-17.
12. Boehringer Ingelheim. Debate 1: Should metformin remain the “foundation therapy” for the majority of patients with T2D? Available from: https://pro.boehringer-ingelheim.com/across-t2d/debate-1-should-metformin-remain-foundation-therapy-majority-patients-t2d Accessed 2021 Feb 17.
13. Consentino F, Grant P, Aboyans V, Bailey C, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Groupl. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020 Jan;41(2):255-323.
14. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2018. Diabetes Care 2018 Jan;41(Suppl 1):S13-27.
15. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Available from: https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html Accessed 2021 Feb 17.
16. Standards of specialized diabetes care. Dedov II, Shestakova MV, Mayorov AY, editors. 8th ed. Diabetes Mellitus 2017 Mar;20(S1):1-121.
17. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet. Diabetes & Endocrinology 2015 Nov;3(11):866-75.
18. Roussel R, Travert F, Pasquet B, Wilson PWF, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg G; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Archives of Internal Medicine 2010 Nov;170(21):1892-9.
19. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovascular Diabetology 2019 Jul;18(1):96.
20. Komaru Y, Takeuchi T, Suzuki L, Asano T, Urayama KY. Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication. Journal of Diabetes and its Complications 2020 Mar;34(3):107511.
21. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circulation. Heart Failure 2011 Jan;4(1):53-8.
22. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity & Metabolism 2019 May;21(5):1199-208.
23. Podhorecka M, Ibanez B, Dmoszyńska A. Metformin – its potential anti-cancer and anti-aging ef fects. Postepy Higieny i Medycyny Doswiadczalnej (Online) 2017 Mar 2;71(0):170-5.
24. Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, Rajpal D, Spivak A, Brown JR, Nunez DJ. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014 Jul;9(7):e100778.
25. US Food & Drug Administration. Questions and answers: NDMA impurities in metformin products. Answers to questions about NDMA impurities found in metformin and FDA’s actions to address the issue. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-metformin-products Accessed 2021 Feb 17.
26. US Food & Drug Administration. FDA updates and press announcements on NDMA in metformin. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin Accessed 2021 Feb 17.
27. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion 2004 Apr;20(4):565-72.
28. Ametov AS. Prevention of type 2 diabetes mellitus. Endocrinology. News, Opinions, Training 2017;4(21):14-25 (In Russian).
29. Derosa G, D’Angelo A, Romano D, Maffioli P. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Design, Development and Therapy 2017 May;11:1481-8.
30. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical Journal 2015 Nov;471(3):307-22.
31. Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Janež A, Kempler P, Konrāde I, Lalić NM, Mankovsky B, Martinka E, Rahelić D, Serafinceanu C, Škrha J, Tankova T, Visockienė Ž. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology 2020 Oct;19(1):185.
32. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2018 Aug;379(7):633-44.
33. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2545-59.
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. The Lancet 1998 Sep;352(9131):837-53.
35. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2560-72.
36. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009 Jan;360(2):129-39.
37. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009 Jul;52(7):1219-26.
38. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019 Sep;322(12):1155-66.
39. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti GV; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 May;31(5):845-51.
40. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy. A retrospective analysis. Diabetes Care 2010 Jun;33(6):1224-9.
41. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005 Oct;28(10):2551-3.
42. Gangji AS, Cukierman T, Gerstain HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007 Feb;30(2):389-94.
43. Müller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Research and Clinical Practice 1995 Aug;28(Suppl):S115-37.
44. Kramer W, Müller G, Girbig, F, Gutjahr U, Kowalewski S, Hartz D. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta 1994 May;1191(2):267-77.
45. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. Journal of Diabetes and its Complications 2002 Jan-Feb;16(1):123-32.
46. Del Guerra S, Parentini C, Bracci C, Lupi R, Marselli L, Aragona M, Navalesi R, Marchetti P. Insulin release form isolated, human islets after acute or prolonged exposure to glimepiride. Acta Diabetologica 2000 Jan;37(3):139-41.
47. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002 Sep;25(9):1607-11.
48. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007 Sep;147(6):386-99.
49. Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67(4):587-97.
50. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Research and Clinical Practice 2007 Apr;76(1):132-8.
51. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity & Metabolism 2011 Mar;13(3):258-67.
52. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism 2013 Apr;15(4):372-82.
53. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Diabetes & Endocrinology 2013 Nov;1(3):208-19.
54. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto R, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019 Jan;321(1):69-79.
55. Garber AJ, Camisasca RP, Jauffret S, Baron MA. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes. Diabetes 2007;56(Suppl 1):A134.
56. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Steinv P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obesity & Metabolism 2007 Sep;9(5):733-45.
57. Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. The Annals of Pharmacotherapy 2003 Nov;37(11):1572-6.
58. Esposito K, Chiodini P, Ceriello A, Giugliano D. A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39 845 patients. Acta Diabetologica 2014 Apr;51(2):305-11.
59. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised. International Journal of Clinical Practice 2011 Nov;65(11):1132-40.
60. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. Journal of Diabetes and its Complications 2000 Jul-Aug;14(4):192-6.
61. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996 Nov;94(9):2297-301.
62. Lee YH, Lee CJ, Lee HS, Choe EY, Lee BW, Ahn CW, Cha BS, Lee HC, Balkau B, Kang ES. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes & Metabolism 2015 Jun;41(3):208-15.
63. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S; ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International 2013 Mar;83(3):517-23.
64. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Manci G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. The New England Journal of Medicine 2014 Oct;371(15):1392-406.
65. Sliwinska A, Rogalska A, Szwed M, Kasznicki J, Jozwiak Z, Drzewoski J. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Molecular Biology Reports 2012 May;39(5):5253-67.
66. Satoh J, Takahashi K, Takizawa Y. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Research and Clinical Practice 2005 Dec;70(3):291-7.
67. Ministry of Health of the Russian Federation; Russian Association of Endocrinologists; National Medical Research Center of Endocrinology. Clinical recommendations. Standards of specialized diabetes care. Dedov II, Shestakova MV, Mayorov AYu, editors. 9th ed. (revised). Moscow, 2019. 216 p. Available from: https://rae-org.ru/system/files/documents/pdf/algoritmy_sd_9-y_vypusk_dopolnennyy_1.pdf Accessed 2021 Feb 17 (In Russian).
68. Esposito K, Chiodini P, Maiorino MI, Capuano A, Cozzoino D, Petrizzo M, Bellastella G, Giugliano D. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open 2015 Feb;5(2):e005892.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]